BRIEF—ICER plans evaluation of Novo Nordisk's oral semaglutide

The USA’s Institute for Clinical and Economic Review (ICER) has posted a Draft Scoping Document outlining a planned review of the comparative clinical effectiveness and value of oral semaglutide from Danish diabetes giant Novo Nordisk and other treatments for type 2 diabetes mellitus.

The report will compare oral semaglutide, a GLP-1 agonist, to three products currently on the market: liraglutide (marketed as Victoza by Novo Nordisk), another GLP-1 agonist; empagliflozin (Jardiance, from Boehringer Ingelheim and Eli Lilly), a SGLT-2 inhibitor; and sitagliptin (Januvia, from Merck & Co), a DPP-4 inhibitor.